Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMP-305B83 + FOLFOX
- Development stage
- Unknown
- Lead developer
- OncXerna Therapeutics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
OMP-305B83 + FOLFOX is a combination of a humanized bispecific monoclonal antibody (navicixizumab, OMP-305B83) and a chemotherapy regimen (FOLFOX: folinic acid, fluorouracil, and oxaliplatin). OMP-305B83 (navicixizumab) targets two receptors: *delta-like ligand 4 (DLL4)* and *vascular endothelial growth factor (VEGF)*, thereby blocking tumor angiogenesis and cancer stem cell growth[2][7][8]. FOLFOX is a standard chemotherapy protocol disrupting DNA synthesis through synergistic effects of its three components[9]. The combination aims to enhance anti-tumor activity by simultaneously targeting angiogenesis and cytotoxic pathways. It is being studied in patients with metastatic colorectal cancer and other solid tumors refractory to standard therapy[1][3][2].
- Other names
- navicixizumab + FOLFOX
02
Targets
Beyond the preview
Go deeper on OMP-305B83 + FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMP-305B83 + FOLFOX.